RESUMEN
Understanding the responses of soil enzyme activities to elevated CO2 concentration and warming can provide a scientific basis for nutrient management of croplands under global climate change. We conducted a pot expe-riment with climate chamber to examine the effects of elevated CO2 concentration and warming and winter wheat growth on soil enzyme activities. There were four climate scenarios: control (CK, 400 µmol·mol-1 CO2 concentration+normal ambient temperature), and CO2 concentration elevation (ECO2, 800 µmol·mol-1 CO2 concentration+normal ambient temperature), elevated temperature (ET, 400 µmol·mol-1 + temperature increased 4 â), and elevated CO2 concentration and temperature (ECO2+T, 800 µmol·mol-1 CO2 concentration + temperature increased 4 â). We measured the activities of soil ß-glucosidase (ßG), ß-N-acetyl glucosidase (NAG), alkaline phosphate (ALP) and polyphenol oxidase (PPO) at four growth stages (JS, jointing stage; AS, anthesis stage; FS, filling stage and MS, maturity stage), with and without winter wheat planting. Without winter wheat planting, there was no significant difference in four kinds of soil enzyme activities between ECO2 and CK, while ET and ECO2+T treatments had significant negative effect on soil enzyme activities. With winter wheat planting, compared with CK, ECO2 and ECO2+T treatments did not affect the activities of those four soil enzyme; but the ET treatment had great impact on soil ALP and PPO activities. The activities of four kinds of soil enzyme were significantly diffe-rent between the ET and ECO2+T treatments. Compared with ET treatment, ECO2+T treatment increased soil ßG activity at the JS, decreased NAG activity at the JS, increased ALP activity at both AS and FS, decreased PPO activity in the JS and increased in the AS. The interaction of elevated CO2 concentration and warming had significant effect on soil NAG and ALP activities with and without winter wheat planting. The interaction of warming and expe-rimental stage had significant effect on four kinds of soil enzyme activities without winter wheat planting, but the interaction of warming and crop growth stage had significant effect on ALP and PPO activities with winter wheat planting. The interaction of elevated CO2 concentration, warming and experimental period had significant effect on soil ßG, ALP and PPO activities without winter wheat growth, while with winter wheat growth, it had significant impact on NAG, ALP and PPO activities. The winter wheat growth had significantly inhibitory effect on ßG, NAG and ALP activities in the two early growth periods (JS+AS), significant promoting effect in the later growth periods (FS+MS), and significantly inhibitory effect on PPO activity during whole growth period. Overall, elevated CO2 concentration did not affect soil enzyme activities, while the elevation of CO2 concentration and temperature on soil enzyme activities differed among the soil enzymes at different growth stages. In addition, the responses of four soil enzyme activities to the interaction of elevated CO2 concentration and warming varied with and without winter wheat planting.
Asunto(s)
Suelo , Triticum , Dióxido de Carbono , Estaciones del Año , TemperaturaRESUMEN
OBJECTIVE: To explore the intervention effect of recombinant human interleukin-11 (rhIL-11) and recombinant human granulocyte-colony stimulating factor (rhG-CSF) on the duration and severity of agranulocytosis in patients with hematological malignancies after chemotherapy, and to analyze the influencing factors. METHODS: The data of hematological malignancy patients treated with rhIL-11 and rhG-CSF after chemotherapy in the hematology department of The First Hospital of Lanzhou University from July 2017 to July 2020 were collected retrospectively. The duration and differences of agranulocytosis in differeent groups were compared by univariate analysis, and the influencing factors of agranulocytosis duration were further analyzed by multiple regression analysis. RESULTS: The duration of agranulocytosis in 97 patients was 6.47±2.93 days. The results of univariate analysis showed that there were no statistical differences in the duration of agranulocytosis among patients with different sex, age, height, weight, body surface area, body mass index (BMI), dose of rhG-CSF, dose of rhIL-11, spontaneous bleeding after administration of rhG-CSF and rhIL-11, and the duration of agranulocytosis in patients with different red blood cell count (RBC), hemoglobin(HGB) level, platelet count (PLT) and absolute neutrophil count (ANC), before administration of rhG-CSF and rhIL-11. There were significant differences in agranulocytosis time among patients with different disease types, chemotherapy cycle, fever after rhG-CSF and rhIL-11 administration, and different white blood cell count (WBC) baseline level before rhG-CSF and rhIL-11 administration (Pï¼0.05). Compared with patients with acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL), patients with acute myeloid leukemia (AML) had the longest duration of agranulocytosis, which was 7.07±3.05 d. Compared with patients with chemotherapy cycles of 4ï¼6 and ≥7, patients with total chemotherapy cycle of 1ï¼3 had the shortest duration of agranulocytosis, which was 5.25±2.48 d. Compared with patients without fever, patients with fever within 1 day after administration of cytokines and patients with fever within 2-5 days after administration of cytokines, the duration of agranulocytosis was the longest in patients with fever 6 days after administration of cytokines, which was 8.85±2.85 d. Compared with patients with WBC baseline <1.0×109/L, (1.0ï¼1.9)×109/L and (2.0ï¼3.9)×109/L, patients with WBC baseline ≥4.0×109/L had the shortest duration of agranulocytosis, which was 4.50±2.56 d. Multiple linear regression analysis showed that chemotherapy cycle, different fever after administration of rhG-CSF and rhIL-11, diagnosis of ALL and NHL, and WBC baseline level before administration of rhG-CSF and rhIL-11 were the influencing factors of the duration of agranulocytosis (Pï¼0.001). CONCLUSION: The risk of prolonged agranulocytosis is higher in patients diagnosed with AML, with more chemotherapy cycles, lower WBC baseline before cytokines administration and fever later after cytokines administration, which should be paid more attention to.
Asunto(s)
Agranulocitosis , Neoplasias Hematológicas , Linfoma no Hodgkin , Factor Estimulante de Colonias de Granulocitos/uso terapéutico , Neoplasias Hematológicas/tratamiento farmacológico , Humanos , Interleucina-11 , Linfoma no Hodgkin/tratamiento farmacológico , Proteínas Recombinantes/uso terapéutico , Estudios RetrospectivosRESUMEN
Oxidative stress is a pathophysiological condition resulting in neurotoxicity, which is possibly associated with neurodegenerative disorders. In this study, the antioxidative effects of the antioxidant astaxanthin (AXT) in combination with huperzine A (HupA), which is used as a cholinesterase inhibitor for the treatment of Alzheimer's disease, were investigated. PC12 cells were treated with either tertbutyl hydroperoxide (TBHP), or with the toxic version of ßamyloid, Aß2535, to induce oxidative stress and neurotoxicity. Cell viability, morphology, lactate dehydrogenase (LDH) release, intracellular accumulation of reactive oxygen species (ROS), superoxide dismutase (SOD) activity and malondialdehyde (MDA) content were determined, while neuroprotection was also monitored using an MTT assay. It was found that combining AXT with HupA significantly increased the viability of PC12 cells, prevented membrane damage (as measured by LDH release), attenuated intracellular ROS formation, increased SOD activity and decreased the level of MDA after TBHP exposure when compared to these drugs administered alone. Pretreatment with HupA and AXT decreased toxic damage produced by Aß2535. These data indicated that combining an antioxidant with a cholinesterase inhibitor increases the degree of neuroprotection; with future investigation this could be a potential therapy used to decrease neurotoxicity in the brain.
Asunto(s)
Alcaloides/farmacología , Enfermedad de Alzheimer/tratamiento farmacológico , Antioxidantes/farmacología , Inhibidores de la Colinesterasa/farmacología , Fármacos Neuroprotectores/farmacología , Sesquiterpenos/farmacología , Enfermedad de Alzheimer/metabolismo , Enfermedad de Alzheimer/patología , Animales , Estrés Oxidativo/efectos de los fármacos , Células PC12 , Ratas , Xantófilas/farmacologíaRESUMEN
The blood-brain barrier (BBB) poses a challenge for the treatment of cerebrovascular diseases including cerebral ischemia-reperfusion injury, Parkinson's syndrome, and cerebral tumors. Nanotechnology has developed as a promising strategy for drug delivery applications to the brain, especially liposomes (Lps) that have shown an intrinsic ability to cross the BBB. Angiopep-2 (ANG), a ligand for low-density lipoprotein receptor-related protein-1 (LRP1), is a good prospect for use as a targeting ligand for brain delivery using Lps. It was also reported that Polysorbate 80 (Tween 80, T80) plays a special role in brain targeting. Moreover, the nasal drug delivery method has attracted increased attention with its brain targeting capability in the clinical treatment of cerebrovascular diseases. The aim of this work was to evaluate the capability of Angiopep-conjugated Polysorbate 80-Coated Liposomes in the delivery of cyclovirobuxine D across the BBB in vitro and in vivo. For this purpose, we first synthesized DSPE-PEG2000-Angiopep-2 then cyclovirobuxine D was encapsulated in Angiopep-conjugated Polysorbate 80-Coated Liposomes (T80-An2-CVB-D-Lps) prepared by thin film evaporation and an ultrasonic technique. Formulations were characterized in terms of encapsulation efficiency, transmission electron microscope (TEM) morphology, size distribution, and zeta potential. Angiopep-conjugated Polysorbate 80-Coated Liposomes enhanced in vitro BBB transport of CVB-D compared to the nontargeted liposomes and the CVB-D solution in the BBB model consisting of brain microvascular endothelial (bEnd.3) cells. To evaluate the brain targeting of T80-An2-CVB-D-Lps in vivo, microdialysis samples were collected from the striatum and blood simultaneously. Rats were dosed with brain-targeting liposomes, CVB-D liposomes and CVB-D solution by intranasal administration and with brain-targeting liposomes by intravenous injection. The results showed that T80-An2-CVB-D-Lps were spherical, small (approximately 80 nm), homogeneously dispersed, negatively charged and possessed a high encapsulation efficiency. T80-An2-CVB-D-Lps crossed the BBB model better than the other treatments did. In addition, in a pharmacodynamic study, there was a higher AUC in the brain after T80-An2-CVB-D-Lps by intranasal administration. In conclusion, T80-An2-Lps can enhance the BBB permeability and improve the transport of CVB-D to the brain. This coadministration strategy can be utilized to enhance the brain accumulation in other cerebrovascular diseases.
Asunto(s)
Encéfalo , Administración Intranasal , Animales , Barrera Hematoencefálica , Medicamentos Herbarios Chinos , Liposomas , Polisorbatos , RatasRESUMEN
The blood-brain barrier (BBB) restricts the delivery of most drugs to the brain. In our previous study, the feasibility of cyclovirobuxine D delivery to the brain by a non-invasive nasal route was evaluated. In this study, a suitable drug delivery system by way of intranasal administration was developed, which could improve brain targeting. First, a formulation of cyclovirobuxine D (CVB-D) based on chitosan nanoparticles (CS-CVB-D-NPs) was prepared by the modified ionotropic gelation method through single-factor screening experiment. The CS-CVB-D-NPs with a entrapment efficiency (EE) of (62.82±2.59)% were found to be of a narrow polydispersity index (PI) (0.19±0.01) and (235.37± 12.71) nm in size, with a zeta potential of (33.9 ± 1.7) mV. The NPs possessed a sustained release characterization with in vitro release of 88.03 ± 2.30% at 24 h. In vivo, the higher AUC0-t(brain) of CS-CVB-D-NPs by intranasal administration revealed the development of a novel brain-targeting delivery method of CVB-D.
Asunto(s)
Barrera Hematoencefálica , Quitosano/química , Medicamentos Herbarios Chinos/administración & dosificación , Nanopartículas , Administración Intranasal , Animales , Encéfalo , Portadores de Fármacos , Sistemas de Liberación de Medicamentos , Tamaño de la PartículaRESUMEN
Cyclosporine A (CsA) is a potent immunosuppressive agent whose clinical usage is limited by nephrotoxicity. Schisandrin B (SchB), isolated from the fruit of Schisandra chinensis, is a natural compound with multiple pharmacological activities that has been shown to attenuate organ injury caused by CsA. Hence, the primary objective of the current study was to evaluate whether SchB has a cytoprotective effect on CsA-induced nephrotoxicity in human proximal tubular epithelial cell line (HK-2). This study demonstrated that pre-incubation of HK-2 cells with 2.5-10.0µM SchB ameliorated CsA induced cytotoxicity caused by oxidative stress as evidenced by reduced levels of intracellular reactive oxygen species (ROS) and LDH release along with increased levels of mitochondrial membrane potential (ΔΨm) and glutathione (GSH). Also, it was demonstrated that nuclear factor erythroid 2-related factor 2 (Nrf2) activation was involved in modulating cellular oxidative stress, where SchB promoted Nrf2 translocation into the nucleus and downstream target gene expression of heme oxygenase-1 (HO-1), NAD(P)H:quinone oxidoreductase 1 (NQO1) and Glutamate-cysteine ligase modifier subunit (GCLM). Additionally, SchB was found to enhance cell survival via reducing apoptosis rate as well as recover the CsA induced blockade of autophagic flux. Collectively, these findings demonstrated that SchB mediated alleviation of CsA induced nephrotoxicity by preventing the accumulation of ROS by way of suppressing oxidative stress, apoptosis and autophagy.